Current advances in diabetic neuropathy: Proteins as therapeutic targets

Gurjeet Kaur; Salaha Osman Ali; Alberto Santos; Tina Okdahl; Anne Marie Wegeberg; Tarunveer S. Ahluwalia; Christian Stevns Hansen; David Wishart; Nicolai J. Wewer Albrechtsen; Birgitte Brock; Troels Staehelin Jensen; Peter Rossing; Christina Brock; Cristina Legido-Quigley; Karolina Sulek

doi:10.1016/j.isci.2025.113466

Current advances in diabetic neuropathy: Proteins as therapeutic targets

Gurjeet Kaur
, Salaha Osman Ali
, Alberto Santos
, Tina Okdahl
, Anne Marie Wegeberg
, Tarunveer S. Ahluwalia
, Christian Stevns Hansen
, David Wishart
, Nicolai J. Wewer Albrechtsen
, Birgitte Brock
, Troels Staehelin Jensen
, Peter Rossing
, Christina Brock
, Cristina Legido-Quigley^*
, Karolina Sulek^*

^*Corresponding author for this work

Department of Clinical Medicine - The Danish Pain Research Center

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaper › Review › Research › peer-review

1 Citation (Scopus)

Abstract

Diabetic neuropathy is a debilitating complication of diabetes characterized by nerve damage that may lead to numbness, foot ulcers, and amputations, and is a major cause of morbidity and mortality in people with diabetes. There are no treatments available for diabetic neuropathy aside from pain management. Recent advances in protein research have identified potential targets associated with the disease development and progression. This review explores the latest studies identifying proteins as possible drug targets in diabetic neuropathy and their role in relevant processes such as polyol metabolism, oxidative stress, and cytokine regulation. Additionally, we provide a comprehensive view of current developments and discoveries at single cell and spatial resolution that have revealed deregulated protein profiles in the dorsal root ganglia, sciatic nerve, trigeminal ganglion, or Schwann cells. Finally, we discuss the benefits of proteomics technologies to identify proteins and associated signaling pathways to better understand the source of diabetic neuropathy.

Original language	English
Article number	113466
Journal	iScience
Volume	28
Issue	10
ISSN	2589-0042
DOIs	https://doi.org/10.1016/j.isci.2025.113466
Publication status	Published - 17 Oct 2025

Keywords

Endocrinology
Human metabolism
Pathology

Access to Document

10.1016/j.isci.2025.113466Licence: CC BY

Library access?

Check availability with the Royal Danish Library

Cite this

Kaur, G., Ali, S. O., Santos, A., Okdahl, T., Wegeberg, A. M., Ahluwalia, T. S., Hansen, C. S., Wishart, D., Wewer Albrechtsen, N. J., Brock, B., Jensen, T. S., Rossing, P., Brock, C., Legido-Quigley, C., & Sulek, K. (2025). Current advances in diabetic neuropathy: Proteins as therapeutic targets. iScience, 28(10), Article 113466. https://doi.org/10.1016/j.isci.2025.113466

@article{f7a75dc0defe4e31989c0522cfb0fa85,

title = "Current advances in diabetic neuropathy: Proteins as therapeutic targets",

abstract = "Diabetic neuropathy is a debilitating complication of diabetes characterized by nerve damage that may lead to numbness, foot ulcers, and amputations, and is a major cause of morbidity and mortality in people with diabetes. There are no treatments available for diabetic neuropathy aside from pain management. Recent advances in protein research have identified potential targets associated with the disease development and progression. This review explores the latest studies identifying proteins as possible drug targets in diabetic neuropathy and their role in relevant processes such as polyol metabolism, oxidative stress, and cytokine regulation. Additionally, we provide a comprehensive view of current developments and discoveries at single cell and spatial resolution that have revealed deregulated protein profiles in the dorsal root ganglia, sciatic nerve, trigeminal ganglion, or Schwann cells. Finally, we discuss the benefits of proteomics technologies to identify proteins and associated signaling pathways to better understand the source of diabetic neuropathy.",

keywords = "Endocrinology, Human metabolism, Pathology",

author = "Gurjeet Kaur and Ali, \{Salaha Osman\} and Alberto Santos and Tina Okdahl and Wegeberg, \{Anne Marie\} and Ahluwalia, \{Tarunveer S.\} and Hansen, \{Christian Stevns\} and David Wishart and \{Wewer Albrechtsen\}, \{Nicolai J.\} and Birgitte Brock and Jensen, \{Troels Staehelin\} and Peter Rossing and Christina Brock and Cristina Legido-Quigley and Karolina Sulek",

year = "2025",

month = oct,

day = "17",

doi = "10.1016/j.isci.2025.113466",

language = "English",

volume = "28",

journal = "iScience",

issn = "2589-0042",

publisher = "Elsevier Inc.",

number = "10",

}

TY - JOUR

T1 - Current advances in diabetic neuropathy

T2 - Proteins as therapeutic targets

AU - Kaur, Gurjeet

AU - Ali, Salaha Osman

AU - Santos, Alberto

AU - Okdahl, Tina

AU - Wegeberg, Anne Marie

AU - Ahluwalia, Tarunveer S.

AU - Hansen, Christian Stevns

AU - Wishart, David

AU - Wewer Albrechtsen, Nicolai J.

AU - Brock, Birgitte

AU - Jensen, Troels Staehelin

AU - Rossing, Peter

AU - Brock, Christina

AU - Legido-Quigley, Cristina

AU - Sulek, Karolina

PY - 2025/10/17

Y1 - 2025/10/17

N2 - Diabetic neuropathy is a debilitating complication of diabetes characterized by nerve damage that may lead to numbness, foot ulcers, and amputations, and is a major cause of morbidity and mortality in people with diabetes. There are no treatments available for diabetic neuropathy aside from pain management. Recent advances in protein research have identified potential targets associated with the disease development and progression. This review explores the latest studies identifying proteins as possible drug targets in diabetic neuropathy and their role in relevant processes such as polyol metabolism, oxidative stress, and cytokine regulation. Additionally, we provide a comprehensive view of current developments and discoveries at single cell and spatial resolution that have revealed deregulated protein profiles in the dorsal root ganglia, sciatic nerve, trigeminal ganglion, or Schwann cells. Finally, we discuss the benefits of proteomics technologies to identify proteins and associated signaling pathways to better understand the source of diabetic neuropathy.

AB - Diabetic neuropathy is a debilitating complication of diabetes characterized by nerve damage that may lead to numbness, foot ulcers, and amputations, and is a major cause of morbidity and mortality in people with diabetes. There are no treatments available for diabetic neuropathy aside from pain management. Recent advances in protein research have identified potential targets associated with the disease development and progression. This review explores the latest studies identifying proteins as possible drug targets in diabetic neuropathy and their role in relevant processes such as polyol metabolism, oxidative stress, and cytokine regulation. Additionally, we provide a comprehensive view of current developments and discoveries at single cell and spatial resolution that have revealed deregulated protein profiles in the dorsal root ganglia, sciatic nerve, trigeminal ganglion, or Schwann cells. Finally, we discuss the benefits of proteomics technologies to identify proteins and associated signaling pathways to better understand the source of diabetic neuropathy.

KW - Endocrinology

KW - Human metabolism

KW - Pathology

UR - https://www.scopus.com/pages/publications/105015349032

U2 - 10.1016/j.isci.2025.113466

DO - 10.1016/j.isci.2025.113466

M3 - Review

AN - SCOPUS:105015349032

SN - 2589-0042

VL - 28

JO - iScience

JF - iScience

IS - 10

M1 - 113466

ER -

Current advances in diabetic neuropathy: Proteins as therapeutic targets

Abstract

Keywords

Access to Document

Library access?

Other files and links

Fingerprint

Cite this